New device sucks blood clots from lungs in acute PE trial

NCT ID NCT06697314

Recruiting now Disease control Sponsor: Angiodynamics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial is testing a device called AlphaVac that suctions blood clots out of the lung arteries in people with acute pulmonary embolism (PE). The study will enroll 256 adults with a confirmed PE and signs of heart strain. The main goals are to see if the device reduces heart strain within 48 hours and to track safety over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AlphaVac multipurpose mechanical aspiration (MMA) F1885 system (a device that suctions out blood clots)
What this could lead to: If it works, this could offer a less invasive way to quickly remove dangerous blood clots from the lungs, potentially reducing heart strain and the need for clot-busting drugs.
What could go wrong: This is a single-arm study with no comparison group, so results may be less reliable. The device may not work for everyone, and there are risks like bleeding or damage to blood vessels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PULMONARY EMBOLISM (PE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary embolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PULMONARY EMBOLISM (PE) PULMONARY EMBOLISM

Contacts and locations

Locations

Poznan University of Medical Sciences
RECRUITING

Poznan, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.